Goldman Sachs
DNA icon

Goldman Sachs’s Ginkgo Bioworks DNA Stock Holding History

Goldman Sachs’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,995
Closed -$66.8K – 5874
2024
Q2 		$66.8K Hold
4,995
– – ﹤0.01% 5442
2024
Q1 		$232K Buy
+4,995
New +$259K ﹤0.01% 5068
2023
Q1 		– Sell
-5,043
Closed -$341K – 5984
2022
Q4 		$341K Hold
5,043
– – ﹤0.01% 5080
2022
Q3 		$629K Hold
5,043
– – ﹤0.01% 4825
2022
Q2 		$480K Buy
5,043
+2,543
+102% +$310K ﹤0.01% 5105
2022
Q1 		$403K Buy
+2,500
New +$487K ﹤0.01% 5471

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Goldman Sachs's DNA Position: Q2 2026 in Review

Goldman Sachs reduced its Ginkgo Bioworks (DNA) stake by 35% in Q2 2026, selling an estimated $2.7M and leaving 607,376 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3714.

Goldman Sachs first reported a position in DNA in Q1 2022 and has held it in 18 quarters since. The position peaked at $12.9M in Q2 2025. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Goldman Sachs held 607,376 shares of Ginkgo Bioworks worth $6.02M as of Q2 2026.
  • Goldman Sachs sold 322,486 Ginkgo Bioworks shares in Q2 2026, an estimated $2.7M.
  • Ginkgo Bioworks made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3714 holding.
  • Goldman Sachs first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 18 quarters since.
  • Goldman Sachs's Ginkgo Bioworks position peaked at $12.9M in Q2 2025.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.